Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Ginkgetin is a biflavonoid that has been isolated from G. biloba and has diverse biological activities, including pro-apoptotic, antiproliferative, anti-inflammatory, anti-atherosclerosis, and neuroprotective properties.1,2,3,4 It inhibits the proliferation of OVCAR-3 ovarian and HeLa cervical cancer cells (EC50s = 3 and 5.2 μg/ml, respectively) and induces apoptosis and caspase-3 cleavage in OVCAR-3 cells when used at a concentration of 3 μg/ml.1 Topical ginkgetin (20 μg/ear) reduces ear edema and prostaglandin E2 (PGE2; Item No. 14010) levels in a mouse model of chronic skin inflammation induced by phorbol 12-myristate 13-acetate (PMA; Item No. 10008014).2 It decreases the thickness of the intima-media and lipid plaque deposition in the thoracic aorta in a rat model of high-fat diet-induced atherosclerosis when administered at a dose of 100 mg/kg.3 Ginkgetin (0.8 mg/kg per day) improves sensorimotor coordination and increases the time spent on a rotating bar in a mouse model of Parkinson's disease induced by MPTP.4
WARNING This product is not for human or veterinary use.
1. Studies on the cytotoxic mechanisms of ginkgetin in a human ovarian adenocarcinoma cell line. Naunyn Schmiedebergs Arch. Pharmacol. 362(10), 82-90 (2000).
2. Effects of anti-
3. Ginkgetin ameliorates experimental atherosclerosis in rats. Biomed. Pharmacother. 102, 510-516 (2018).
4. Neuroprotective effects of ginkgetin against neuroinjury in Parkinson’s disease model induced by MPTP via chelating iron. Free Radic. Res. 49(9), 1069-1080 (2015).